NASDAQ:INGN Inogen (INGN) Stock Price, News & Analysis $6.58 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.57 -0.01 (-0.21%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inogen Stock (NASDAQ:INGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inogen alerts:Sign Up Key Stats Today's Range$6.45▼$6.7250-Day Range$6.10▼$7.3552-Week Range$5.34▼$9.13Volume437,289 shsAverage Volume349,363 shsMarket Capitalization$178.19 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingModerate Buy Company Overview Inogen, Inc. (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go. Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen. These devices are engineered to be lightweight, battery-powered and FAA-approved for in-flight use, addressing both clinical efficacy and user convenience. The company also offers supporting accessories such as batteries, chargers and carrying cases to enhance patient experience and ensure uninterrupted oxygen delivery. Founded in 2001 and headquartered in Goleta, California, Inogen has obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval for distribution in Europe. The company serves a global customer base through direct-to-consumer sales channels as well as partnerships with home healthcare providers and distributors across North America, Europe and parts of the Asia-Pacific region. Inogen is led by President and Chief Executive Officer Scott Wilkinson, under whose leadership the company has invested in research and development to expand its product portfolio and support emerging digital health initiatives.AI Generated. May Contain Errors. Read More Inogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreINGN MarketRank™: Inogen scored higher than 74% of companies evaluated by MarketBeat, and ranked 328th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingInogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialInogen has a consensus price target of $14.00, representing about 112.8% upside from its current price of $6.58.Amount of Analyst CoverageInogen has only been the subject of 2 research reports in the past 90 days.Read more about Inogen's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($0.72) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inogen's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.04% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 2.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inogen has recently decreased by 23.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentInogen has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest1 people have searched for INGN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Inogen is held by insiders.Percentage Held by Institutions89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inogen's insider trading history. Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INGN Stock News HeadlinesInogen Earnings Call: International Strength Amid U.S. StrainMay 20, 2026 | tipranks.comInogen (NASDAQ:INGN) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?May 19, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 27 at 1:00 AM | Profits Run (Ad)How The Inogen (INGN) Story Is Shifting With New Targets And Execution QuestionsMay 12, 2026 | finance.yahoo.comInogen Inc. Earnings Call Highlights Transition PhaseMay 8, 2026 | tipranks.comInogen reaffirms 2026 revenue outlook of $366M-$373M as it scales Aurora and Voxi 5May 8, 2026 | seekingalpha.comInogen, Inc. (INGN) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comInogen Maintains Buy Rating as Analyst Reaffirms $12 Price Target on Solid Q1 and Growth CatalystsMay 8, 2026 | tipranks.comSee More Headlines INGN Stock Analysis - Frequently Asked Questions How have INGN shares performed this year? Inogen's stock was trading at $6.72 at the beginning of the year. Since then, INGN shares have decreased by 2.1% and is now trading at $6.58. How were Inogen's earnings last quarter? Inogen, Inc (NASDAQ:INGN) released its earnings results on Thursday, May, 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.06. The medical technology company had revenue of $85.11 million for the quarter, compared to analysts' expectations of $82.35 million. Inogen had a negative net margin of 7.08% and a negative trailing twelve-month return on equity of 12.90%. Read the conference call transcript. When did Inogen IPO? Inogen (INGN) raised $75 million in an initial public offering (IPO) on Friday, February 14th 2014. The company issued 4,411,763 shares at a price of $16.00-$18.00 per share. Who are Inogen's major shareholders? Inogen's top institutional investors include Arrowstreet Capital Limited Partnership (2.16%), Dimensional Fund Advisors LP (1.87%), Renaissance Technologies LLC (1.77%) and Perkins Capital Management Inc. (0.73%). View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inogen investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/07/2026Today5/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 INGN's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:INGN CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,030Year Founded2001Price Target and Rating Average Price Target for Inogen$14.00 High Price Target$14.00 Low Price Target$14.00 Potential Upside/Downside+112.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.75 million Net Margins-7.08% Pretax Margin-7.28% Return on Equity-12.90% Return on Assets-8.27% Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio2.70 Sales & Book Value Annual Sales$348.67 million Price / Sales0.51 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book0.97Miscellaneous Outstanding Shares27,080,000Free Float26,398,000Market Cap$178.19 million OptionableOptionable Beta1.64 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:INGN) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
